Use of Hypertonic Continuous Venovenous  Hemodiafiltration to Control Intracranial Hypertension in  an End-Stage Renal Disease Patient by Rifkin, Stephen I. et al.
SAGE-Hindawi Access to Research
International Journal of Nephrology
Volume 2010, Article ID 391656, 2 pages
doi:10.4061/2010/391656
Case Report
Use of Hypertonic Continuous Venovenous
Hemodiaﬁltration to Control Intracranial Hypertensionin
an End-Stage Renal Disease Patient
Stephen I. Rifkin,1 Al iR .M al e k , 2 andReza Behrouz3
1Division of Nephrology, Department of Internal Medicine, University of South Florida College of Medicine, Tampa, 33612, USA
2Interventional Neurology Program, Comprehensive Stroke Center, St. Mary’s Medical Center, West Palm Beach, 33407, USA
3Section for Neurological Critical Care, Department of Neurology, University of South Florida College of Medicine,
Tampa, 33612, USA
Correspondence should be addressed to Stephen I. Rifkin, srifkin@health.usf.edu
Received 4 January 2010; Revised 24 May 2010; Accepted 15 June 2010
Academic Editor: Alejandro Mart´ ın-Malo
Copyright © 2010 Stephen I. Rifkin et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Continuous venovenous hemodiaﬁltration (CVVHDF) using solutions designed to maintain hypernatremia is described in an
end-stage renal disease (ESRD) patient with cerebral edema (CE) due to an intracerebral hemorrhage (ICH). Hypernatremia was
readily achieved and maintained without complication. CVVHDF should be considered as an alternative treatment option in
ESRD patients with cerebral edema who require hypertonic saline therapy.
1.Introduction
Osmotherapy is an option for the treatment of cerebral
edemaduetoacutebraininjury.Itisusedtopreventprogres-
sion of CE and lower intracerebral pressure (ICP). Mannitol
andhypertonicsaline(HTS)arethedrugscurrentlyavailable
for this purpose [1]. Mannitol would be inappropriate in a
patient with end-stage renal disease (ESRD) due to its accu-
mulationinapatientwithoutexcretoryfunction.Hypertonic
saline would be acceptable only as long as its accumulation
andtheexcessextracellularvolumegeneratedbytheresulting
hypertonicity could be controlled. A patient with ESRD
is described who developed an ICH with subsequent CE
andwasplacedoncontinuousvenovenoushemodiaﬁltration
(CVVHDF) using ﬂuids specially designed to maintain a
hypertonic state with goal serum sodium of approximately
150–155meq/L.
2.CaseReport
The patient is a 45-year-old male admitted after developing
a headache, slurred speech, and left hemiparesis during his
routine hemodialysis treatment. A CT scan of the brain
showed a 4.4 × 2.5cm area of hyperattenuation in the
right basal ganglia area, moderate edema associated with
the ICH, and mass eﬀect with a 2mm right-to-left midline
shift. His admission serum sodium was 139meq/L. He
had been on hemodialysis for the past 7 to 8 years. He
was known to be hepatitis C antibody and hepatitis B
antigen positive. He also had a history of hypertension
and asthma. The day after admission a repeat CT scan
demonstrated that the edema and mass eﬀect had increased
andthatthemidlineshifthadincreasedto10mm.Becauseof
compression on the third ventricle, mild hydrocephalus had
also developed. A ventriculostomy catheter was inserted the
day after admission. That same morning, he was started on
continuous venovenous hemodiaﬁltration (CVVHDF) using
regional citrate anticoagulation. Our standard CVVHDF
protocol is based on that of Mehta et al. [2]b u tu s e sa
ﬁxed rate of citrate. The standard protocol has a dialysate
sodium of 117meq/L and a predilution replacement ﬂuid
sodium of 135meq/L. This was adjusted to a dialysate
sodium of 127meq/L and a predilution replacement ﬂuid
sodium of 155meq/L. In addition, shortly after the initiation2 International Journal of Nephrology
ofCVVHDF,thepatientwasgivena250ccbolusof3%saline
followed by an infusion at 100cc/hr to quickly elevate his
serum sodium. The infusion was discontinued the next day,
and the patient was maintained on hypertonic CVVHDF.
CVVHDF was continued for a total of four days. Lab
values were frequently monitored. Minor adjustments to
the solutions were made to keep the serum sodium near
the goal of approximately 155meq/L. Peak serum sodium
was 157meq/L. Serum sodium was successfully maintained
in the goal range. Intracranial pressure and cerebral perfu-
sion pressure were frequently monitored and were always
satisfactory. Unfortunately, the patient’s neurologic status
did not improve. After four days of CVVHDF, the decision
was made to allow the serum sodium to slowly normalize.
CVVHDF was stopped, and the patient was placed back on
intermittent hemodialysis. Dialysate sodium of 147meq/L
wasusedforonehemodialysistreatmentandthen145meq/L
was used for the next treatment. The serum sodium came
down to 144meq/L. Several followup head CT scans showed
no improvement. At that point, the family requested further
therapy be discontinued, and the patient expired shortly
thereafter.
3. Discussion
Osmotherapy is an eﬀective treatment option to control CE
and reduce intracranial pressure in patients with acute brain
injury. Mannitol and HTS are the usual drugs used. Both can
have signiﬁcant side eﬀects. Mannitol has been reported to
cause a variety of electrolyte disturbances and acute renal
failure [3]. In an ESRD patient who is anuric, mannitol
could accumulate in the brain tissue and paradoxically
increase CE. HTS causes hypernatremia and extracellular
volume expansion and can cause metabolic acidosis and
hypokalemia among other side eﬀects [4]. HTS has been
showntobeeﬀectiveinpatientsresistanttomannitoltherapy
[4, 5]. HTS may also have a beneﬁcial eﬀect on mortality
in the treatment of raised ICP when compared to mannitol
[6]. It has been reported that serum tonicity as high as
365mosm/lcanbesafelyachievedwithHTStherapywhereas
mannitol therapy is limited to a maximum of 320mosm/l
[7]. When hypernatremia, whether or not a consequence of
osmotic therapy, was evaluated in patients in a neurologic
ICU, it was an independent predictor of mortality only when
the peak serum sodium exceeded 160meq/L [8].
It has recently been suggested that continuous renal
replacement therapy, due to greater cardiovascular and
intracranialstability,isthepreferredmethodtotreatpatients
with acute brain injury and renal failure [9]. We treated our
patient with CVVHDF using speciﬁcally prepared solutions.
Ourpharmacydoesnotusecommerciallypreparedsolutions
but rather uses an automatic compounder to custom mix
the ordered solutions. Thus, it was straightforward for the
pharmacy to mix the requested solutions for hypertonic
CVVHDF. This simpliﬁed the patient’s regimen as the need
for a constant hypertonic saline drip was eliminated. We
observed no untoward eﬀects from the hypertonic dialysis,
and the serum sodium was readily maintained in the goal
range. We are aware of only one similar report in the liter-
ature, that of Hofmann et al. using continuous venovenous
hemoﬁltration (CVVH) and that is only reported in abstract
form [10]. We feel that hypertonic CVVHDF should be
considered a reasonable treatment option for acute brain
injury in patients with renal failure.
4. Conclusion
CVVHDF with solutions designed to induce hypernatremia
was used to treat an ESRD patient with CE due to an
ICH. We were able to maintain the serum sodium at goal,
and no adverse eﬀects of the procedure were noted. We
suggest hypertonic CVVHDF be considered an option in
the treatment of ESRD patients with CE due to acute brain
injury.
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